Progression Free Survival Clinical Trial
Official title:
A Phase 2 Study of Target-Guided Personalized Chemotherapy in Metastatic Colorectal Cancer Patients
Treatment options for patients with colorectal cancer (CRC) have increased in the last
years. However, there are no validated prospective molecular markers in CRC to select which
agents are better to treat any individual case. The conventional first-line treatment in CRC
patients in clinical studies get a proportion of patients free of progression at 12 months
ranging from 35-40% with a median of 9 months of free disease progression.
The aim of this study is to demonstrate that the identification of therapeutic targets in
real time and their prospectively use to customize the treatment get a proportion of
colorectal metastatic patients patients free of progression disease at 12 months of 50%.
n/a
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03748680 -
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06338683 -
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03100955 -
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT03769935 -
Maintenance Therapy for Small-cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05477797 -
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
|
N/A | |
| Completed |
NCT02959749 -
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
|
Phase 2/Phase 3 |